Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) FCF Margin (2016 - 2025)

Editas Medicine (EDIT) has disclosed FCF Margin for 11 consecutive years, with 416.15% as the latest value for Q3 2025.

  • Quarterly FCF Margin rose 9928877.0% to 416.15% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 370.7% through Sep 2025, down 6713.0% year-over-year, with the annual reading at 650.95% for FY2024, 48068.0% down from the prior year.
  • FCF Margin for Q3 2025 was 416.15% at Editas Medicine, up from 1400.17% in the prior quarter.
  • The five-year high for FCF Margin was 32.76% in Q4 2023, with the low at 115757.14% in Q3 2022.
  • Average FCF Margin over 5 years is 13201.31%, with a median of 729.97% recorded in 2022.
  • The sharpest move saw FCF Margin crashed -11513436bps in 2022, then soared 11508814bps in 2023.
  • Over 5 years, FCF Margin stood at 336.53% in 2021, then plummeted by -83bps to 615.35% in 2022, then skyrocketed by 95bps to 32.76% in 2023, then tumbled by -324bps to 139.0% in 2024, then plummeted by -199bps to 416.15% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 416.15%, 1400.17%, and 1028.62% for Q3 2025, Q2 2025, and Q1 2025 respectively.